ReviewThe international journal of neuropsychopharmacology2013
Serotonergic hallucinogens as translational models relevant to schizophrenia.
Review in The international journal of neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 65 citations in OpenAlex.
- Psychedelic-Related Psychosis: From Model Psychosis to Psychotherapy.Current topics in behavioral neurosciences · 2026Review
- Distinctive patterns of G protein coupling induced by the structurally similar 5-HTMolecular pharmacology · 2025Article
- Pharmaco-toxicological effects of the novel tryptamine hallucinogen 5-MeO-MiPT on motor, sensorimotor, physiological, and cardiorespiratory parameters in mice-from a human poisoning case to the preclinical evidence.Psychopharmacology · 2024Article
- Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.European addiction research · 2024Review
- Dose-dependent LSD effects on cortical/thalamic and cerebellar activity: brain oxygen level-dependent fMRI study in awake rats.Brain communications · 2024Article
- Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia.Schizophrenia bulletin · 2023Review
- Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats.Molecular psychiatry · 2023Article
- Psychosis and psychedelics: Historical entanglements and contemporary contrasts.Transcultural psychiatry · 2022Article
- A neurobiological perspective on social influence: Serotonin and social adaptation.Journal of neurochemistry · 2022Review
- Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Effects of combined 5-HTPsychopharmacology · 2020Article
- The Role of Zebrafish and Laboratory Rodents in Schizophrenia Research.Frontiers in psychiatry · 2020Review
- Behavioral and Serotonergic Changes in the Frontal Cortex Following Methamphetamine Self-Administration.The international journal of neuropsychopharmacology · 2018Article
- Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).Drug testing and analysis · 2018Article
- Dimensions of consciousness and the psychedelic state.Neuroscience of consciousness · 2018Article
- Differential effects of antipsychotic and propsychotic drugs on prepulse inhibition and locomotor activity in Roman high- (RHA) and low-avoidance (RLA) rats.Psychopharmacology · 2017Article
- Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.Drug testing and analysis · 2017Article
- Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.Current neuropharmacology · 2017Review
- d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.International journal of molecular sciences · 2016Review
- Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges.Psychopharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
One of the oldest models of schizophrenia is based on the effects of serotonergic hallucinogens such as mescaline, psilocybin, and (+)-lysergic acid diethylamide (LSD), which act through the serotonin 5-HT(2A) receptor. These compounds produce a 'model psychosis' in normal individuals that resembles at least some of the positive symptoms of schizophrenia. Based on these similarities, and because evidence has emerged that the serotonergic system plays a role in the pathogenesis of schizophrenia in some patients, animal models relevant to schizophrenia have been developed based on hallucinogen effects. Here we review the behavioural effects of hallucinogens in four of those models, the receptor and neurochemical mechanisms for the effects and their translational relevance. Despite the difficulty of modelling hallucinogen effects in nonverbal species, animal models of schizophrenia based on hallucinogens have yielded important insights into the linkage between 5-HT and schizophrenia and have helped to identify receptor targets and interactions that could be exploited in the development of new therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.